Global Liquid Biopsy Diagnostics Market Analysis and Forecast (2020-2035)
The global liquid biopsy diagnostics market is recognized as a transformative force in oncology, leveraging minimally invasive approaches for early cancer detection, therapy monitoring, and personalized treatment selection. Based on circulating tumor cells (CTCs), ctDNA, exosomes, and other biomarkers, liquid biopsies are rapidly gaining traction. Driven by advancements in next-generation sequencing and PCR-based detection, the market is witnessing growing adoption among hospitals, diagnostic labs, and research institutes. The increasing global cancer burden, coupled with technological advances and a preference for non-invasive diagnostic tools, are fueling robust market expansion through to 2035.
Latest Market Dynamics
Key Drivers
- Increasing prevalence of cancer worldwide is substantially boosting demand for liquid biopsy diagnostics. According to recent data, Guardant Health has expanded collaborations in 2024 to address solid tumor detection, supporting earlier interventions and better prognoses.
- Technological advancements in next-generation sequencing (NGS) and digital PCR have significantly enhanced both the sensitivity and specificity of liquid biopsy assays. In June 2024, Illumina introduced improved NGS panels for ctDNA analysis, accelerating adoption among oncologists and diagnostic providers.
Key Trends
- Integration of AI and machine learning into liquid biopsy data interpretation is enabling more accurate and rapid cancer diagnostics. Roche Diagnostics' deployment of AI-powered workflows in early 2024 led to streamlined liquid biopsy reporting for clinicians across Europe.
- Expansion of multi-cancer early detection panels, such as those by Foundation Medicine, is setting a new trend toward comprehensive screening approaches, particularly favored by population health programs in North America and APAC regions.
Key Opportunities
- The untapped potential of emerging markets in Asia-Pacific is presenting substantial growth opportunities. QIAGEN forged a strategic partnership with Indian healthcare providers in July 2024 to deploy their liquid biopsy solutions in high-burden regions.
- Growth in companion diagnostics is a vital opportunity, with Thermo Fisher Scientific collaborating with pharmaceutical companies in August 2024 to co-develop liquid biopsy-based companion diagnostics for targeted therapies.
Key Challenges
- Regulatory hurdles and inconsistent standards across regions remain significant challenges. Bio-Rad Laboratories has faced extended approval timelines for its digital PCR kits in multiple countries in 2024.
- Limited awareness and insufficient reimbursement schemes in some regions are slowing adoption. For example, Freenome has been actively leading awareness campaigns in parts of Eastern Europe, yet market penetration lags compared to Western regions.
Key Restraints
- Concerns regarding data privacy and sharing of genetic information continue to restrain market growth. Natera reported in June 2024 that navigating new data protection regulations increased operational complexity.
- High costs associated with advanced liquid biopsy platforms can limit accessibility. Myriad Genetics revised their 2024 pricing models to support equitable adoption, but financial barriers persist in low-resource settings.
Global Liquid Biopsy Diagnostics Market Share by Type, 2025
The market by type is dominated by Circulating Tumor DNA (ctDNA), which holds the largest segment in 2025, reflecting strong adoption as an early cancer diagnostic and monitoring tool. Circulating Tumor Cells (CTCs) and Cell-Free DNA (cfDNA) follow, driven by ongoing clinical validations and expanding application in both solid and hematologic cancers. Exosomes and extracellular vesicles are registering modest growth, with research organizations driving innovation in their use for personalized oncology.
Global Liquid Biopsy Diagnostics Market Share by Application, 2025
Cancer diagnosis is the leading application for liquid biopsies in 2025, accounting for 38% of total market share, propelled by physician preference for faster, less invasive tests. Treatment monitoring is rapidly climbing, as real-time molecular insights become standard for therapy adjustment. Early detection and risk assessment further emphasize liquid biopsy’s utility in proactive patient care, while therapy selection is becoming central to personalized medicine in clinical oncology.
Global Liquid Biopsy Diagnostics Market Revenue (USD Million), 2020-2035
The liquid biopsy diagnostics market is slated for sustained revenue growth between 2020 and 2035. Starting at USD 1,850 Million in 2020, market revenues rise sharply, crossing USD 3,470 Million by 2025, propelled by breakthrough diagnostic advancements and increased clinical adoption. By 2030, the market surges beyond USD 7,500 Million, reaching an estimated USD 15,400 Million by 2035. This trajectory reflects expanding clinical applications, entry into emerging markets, and the ongoing shift toward preventative screening and personalized oncology worldwide.
Global Liquid Biopsy Diagnostics Market YOY (%) Growth, 2020-2035
Year-on-year growth in the global liquid biopsy diagnostics market maintains a robust profile through 2025, with a peak YOY of 18% between 2023-2024, fueled by new FDA approvals and expanded reimbursement in key markets. From 2026 onwards, YOY growth rates gradually normalize between 8% and 12%, reflecting a maturing market with steady innovation cycles and consistent clinical demand, leading to sustainable long-term expansion.
Global Liquid Biopsy Diagnostics Market Share by Regions, 2025
North America leads the global market in 2025, accounting for 42% of the total market share due to established healthcare infrastructure, higher cancer screening rates, and rapid access to next-gen diagnostic technologies. Europe follows at 29%, benefitting from supportive national cancer control strategies and cross-border collaborations. Asia-Pacific, with a 20% share, is poised for the fastest growth, supported by large patient pools and increasing government investments in precision medicine.
Global Liquid Biopsy Diagnostics Market Players Share (%), 2025
Guardant Health leads the competitive landscape in 2025 with 19% market share, bolstered by its robust platform portfolio and global expansion strategies. Foundation Medicine holds 13%, while Roche Diagnostics closely follows at 12%. Other significant players include Illumina (10%) and Thermo Fisher Scientific (8%), with the collective remainder representing a dynamic ecosystem of specialized diagnostics, tech innovators, and regional firms.
Global Liquid Biopsy Diagnostics Market Buyer Share (%), 2025
Hospitals are the primary buyers, accounting for 41% of the market in 2025 as most liquid biopsy procedures are integrated into clinical workflows. Diagnostic laboratories follow with 29%, leveraging advanced analytical platforms for comprehensive cancer screening. Research institutes, CROs, and academic centers comprise the rest of the market, driving continued innovation and translational research in liquid biopsy applications.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 3930 |
| Regions | North America, Europe, Asia-Pacific, South America, Middle East, Africa |
| Segments | Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Exosomes, Extracellular Vesicles, Cell-Free DNA (cfDNA), Others, Cancer Diagnosis, Treatment Monitoring, Risk Assessment, Early Detection, Therapy Selection, Others, Hospitals, Diagnostic Laboratories, Research Institutes, CROs, Academic Institutes, Others, Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Digital PCR, Microarray, In Situ Hybridization, Others, Small, Medium, Large |
| Players | Guardant Health, Foundation Medicine, Biocept, QIAGEN, Roche Diagnostics, Illumina, Thermo Fisher Scientific, Myriad Genetics, Bio-Rad Laboratories, Genomic Health, Freenome, Liquid Biotech USA, Natera, Menarini Silicon Biosystems, Epigenomics AG |
Key Recent Developments
- 04 June 2024: Guardant Health partners with Memorial Sloan Kettering to launch a multi-cancer detection study.
- 20 July 2024: QIAGEN announces the rollout of a new liquid biopsy platform in collaboration with Indian diagnostic labs.
- 08 August 2024: Thermo Fisher Scientific signs a strategic agreement with a global pharma firm for developing companion diagnostics using liquid biopsy.
- 15 September 2024: Roche Diagnostics unveils an AI-powered workflow for real-time liquid biopsy analysis across Europe.
- 30 June 2024: Illumina expands its ctDNA-based NGS panels, targeted at improving the sensitivity of early cancer detection assays.
